Literature DB >> 3167868

Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.

A Bizzi1, A M Codegoni, F Landoni, G Marelli, S Marsoni, A M Spina, W Torri, C Mangioni.   

Abstract

Estrogen receptor (ER) and progestin receptor were measured in samples of tumors obtained at first laparotomy from 97 previously untreated patients suffering with a primary ovarian epithelial tumor, for whom a 3-year follow-up was available. The presence or absence of steroid receptors (threshold arbitrarily fixed at 10 fmol/mg of cytoplasmic protein) was determined by the dextran coated charcoal method and related to a number of patient characteristics such as the residual disease (cutoff, 2 cm), histological type, International Federation of Gynecologists and Obstetricians grade and stage, and age. Results were analyzed by univariate and multivariate methods. (a) The tumor ER positivity was associated with better survival; progestin receptor showed a similar trend but did not reach statistical significance. (b) After stratification for residual tumor the association ER positivity/better survival was still statistically significant in the subset of patients with residual tumor greater than 2 cm. (c) When the median survival times were considered it became apparent that progestin receptor absence nullified the effect associated with positive ER. (d) Multivariate analysis confirmed that among the variables considered the main determinants of prognosis were the size of the residual tumor, serous histological type, and positive ER.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167868

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.

Authors:  Chun Wai Ng; Kwong-Kwok Wong
Journal:  J Ovarian Res       Date:  2022-05-24       Impact factor: 5.506

2.  GPR30 predicts poor survival for ovarian cancer.

Authors:  Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz
Journal:  Gynecol Oncol       Date:  2009-06-06       Impact factor: 5.482

3.  Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.

Authors:  Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

4.  Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.

Authors:  J Akahira; T Inoue; T Suzuki; K Ito; R Konno; S Sato; T Moriya; K Okamura; A Yajima; H Sasano
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

5.  Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  Zhaojun Shen; Hui Luo; Saisai Li; Bo Sheng; Menghuang Zhao; Haiyan Zhu; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-05-29

6.  Expression of the pNR-2/pS2 protein in diverse human epithelial tumours.

Authors:  J A Henry; M K Bennett; N H Piggott; D L Levett; F E May; B R Westley
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

7.  Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors:  J-I Akahira; M Aoki; T Suzuki; T Moriya; H Niikura; K Ito; S Inoue; K Okamura; H Sasano; N Yaegashi
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.